Male Urinary Symptoms May Indicate Mortality Risk Over Time

TUESDAY, May 3, 2022 (HealthDay News) -- Moderate-to-severe male lower urinary tract symptoms (LUTS) are associated with an increased risk of death during long-term follow-up, according to a study published online April 26 in The Journal of Urology.
Jonne Åkerla, M.D., from Tampere University Hospital in Finland, and colleagues evaluated LUTS-associated mortality among Finnish men. Analysis included responses from 1,167 men (aged 50, 60, and 70 years in 1994), with repeat surveys conducted in 1999, 2004, 2009, and 2015.
The researchers observed an association for increased mortality with overall voiding and storage LUTS, daytime frequency, and urgency incontinence, with adjusted hazard ratios of 1.19 (95 percent confidence interval [CI], 1.00 to 1.40), 1.35 (1.13 to 1.62), 1.31 (1.09 to 1.58) and 2.19 (1.42 to 3.37), respectively, when limited to moderate and severe symptoms. When disregarding symptom severity and bother, voiding LUTS were associated with decreased mortality (HR, 0.82; 95 percent CI, 0.67 to 1.00), while daytime frequency and nocturia were associated with increased mortality (HRs, 1.31 [95 percent CI, 1.09 to 1.58] and 1.52 [95 percent CI, 1.21 to 1.91], respectively). When examining bothersome daytime frequency and nocturia, excess mortality tended to be slightly higher (HRs, 1.86 [95 percent CI, 1.41 to 2.47] and 1.88 [95 percent CI, 1.38 to 2.58], respectively).
"The lack of association between symptom bother and mortality possibly reinforces the very subjective nature of bother as a construct compared to more objectively measured symptom severity," the authors write.
Related Posts
Diez minutos adicionales de actividad diaria podrían salvar 110,000 vidas al año en EE. UU.
MARTES, 25 de enero de 2022 (HealthDay News) -- Estadounidenses, levántense de...
Dormir mal más una susceptibilidad genética puede aumentar el riesgo de asma de algunas personas
MARTES, 4 de abril de 2023 (HealthDay News) -- Dormir bien de noche es...
La ’emergencia’ por la COVID terminó: esto es lo que debe saber
LUNES, 15 de mayo de 2023 (HealthDay News) -- Aunque la emergencia de salud...
ASCO: Adding Atezolizumab to Cabozantinib No Benefit in Advanced Renal Cancer
FRIDAY, June 9, 2023 (HealthDay News) -- For patients with locally advanced or...
